Genepath is the leading innovator in single software solutions for genomics
Cross-disciplinary expertise in bioinformatics, software engineering and genomics for integrated, high-throughput testing
WHO ARE WE?
Dedicated to improving genomics through enabling high throughput testing
advanced LIMS functionality
We are world leaders in software which integrates LIMS, automation control, bioinformatics and reporting to unify NGS workflows.
Global leaders
Over 20 years experience in genomics and software engineering, leaders in peer reviewed research in genomic newborn screening.
Clinical validation excellence
Atlas accuracy >99% published 2017, feasibility of high throughput genomic newborn screening published 2023, and clinical validation published 2026.
Management team
Dr Bennett Shum
Chief Executive Officer
-
He trained at Garvan Institute and Harvard Medical School and is Adjunct Senior Lecturer at University of New South Wales. Ben helped implement genomic testing technology to hospitals throughout Australia and is passionate about developing genomic solutions that can save lives across the globe.
BMedSci(Hons), PhD, MBA
Dr Glenn Bennett
Chief Medical Officer
-
He has cross-disciplinary expertise as a doctor and scientist with an interest in public heath. With over 15 years experience in the public health sector, his strength is driving health system-wide uptake of innovative medical technology.
MB BS BSc(Med)(Hons) FACEM MBA
Ilya Henner
Chief Technology Officer
-
He is passionate about making software easy to use. With over a decade experience in a large biotech company, Ilya’s mission was to design and code, integrated software for newborn screening that integrated wetlab and drylab in a seamless use experience, resulting in a clinical report.
BTech(Biotech)
Advisory board
Ishani Chattopadhyay
-
Ishani has a career spanning over 20+ years across Australia, USA, UK, and India/South Asia with a focus on scaling startups, strategic advisory, enterprise development/operations, innovation, and investment.
Ishani started her career in management consulting in Australia and the USA. She ran the India/Middle East climate change technology operations for a Fortune 500 power company and managed the Asia operations of a USD $60M global impact fund. Recently, Ishani has run her own enterprise primarily focused on advisory support for SMES/start-ups and scale ups, seed funding and strategy and governance and supported over 100+ startups/scaleups.
BSc BE MBA
Paulette Barahona
-
Paulette is a senior molecular geneticist with over a decade experience in the development and validation of genetic tests. She pioneered the development of next-generation DNA sequencing to detect major chromosomal abnormalities in IVF embryos (PGT-A) and commercialised a breakthrough preconception expanded carrier screening test while working at one of Australia’s largest IVF clinics. Paulette is passionate about making genetic testing accessible for everyone.
BSci (Genetics), MMed Sci (Drug Development)
Dr Don Leigh
-
Don was a co-founder of one of Australia’s first private sector genetic testing laboratories, DNAlabs which he exited following a trade sale in the late 1990s. At Sydney IVF, now Genea, as Director of Molecular Genetics he developed and commercialised a number of proprietary genetic tests.
PhD
Nathan Cleary
-
Nathan is a finance, investment and M&A professional with over 20 years of finance and direct investment (private equity and infrastructure) experience. Nathan has spent most of his career working in the private equity industry. Since 2012, Nathan has worked at a number of corporates including at Boral Limited and at Right2Drive. Nathan was involved in the start-up of Right2Drive that was subsequently sold to Eclipx Limited in May 2016 for A$67 million. Nathan is currently the CFO of a leading Australian land lease communities business, providing secure, affordable, quality lifestyle communities for Australians.
B.Bus, CPA, CFA Charterholder
Prof Deon Venter
-
Deon is a histopathologist with a PhD in Molecular Genetics. He is a Professor of Pathology, School of Medicine, The University of Wollongong, NSW and a pathology advisor at Genepath. His interest is in utilising the interface between biological science and pathology to improve medical practice. Disciplines utilised during his career have included: Histopathology, perinatal pathology, genetics, genomics, computational biology, translational research, management, biotechnology and business management.
MB CHB, FRCPA
Dr Emre Basar
-
Emre is a physician-scientist with nearly 15 years of experience in the pharmaceutical industry. After graduating from medical school in Germany, Emre pursued a PhD in Immunology at Harvard Medical School, focusing on the translational application of RNAi in cancer and HIV research. During that time, he co-founded InterNations.org, an expat-focused social networking platform that was acquired by XING AG in 2017. Since 2012, Emre has held several positions of increasing responsibility within the pharmaceutical industry focusing on clinical trials and obtaining regulatory approval for novel therapeutics.